The United States Patent and Trademark Office has approved a patent from Israel’s Oramed for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.” The patent is the basis for Oramed’s ORMD-0801 oral insulin for the early treatment … Continue reading →

Israeli bio-tech Oramed has announced that its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes met all primary and secondary endpoints. The Phase 2b study will be carried out later this … Continue reading →

Israeli biotech Ormed is developing oral medicines to treat conditions that normally require injections. Its flagship product, the ORMD-0801 insulin capsule for Type 1 (juvenile) diabetes has just successfully completed clinical trials. Ormed’s share price rose 115 percent on the … Continue reading →